Innocan Pharma Completes Additional Debenture Offering with Major Shareholder
Innocan Pharma Corporation, a significant player in the pharmaceutical and wellness sectors, has recently announced the closure of an additional debenture offering aimed at strengthening its capital structure. The company, headquartered in Herzliya, Israel, successfully finalized a debenture valued at US $200,000 with its largest shareholder, Tamar Innovest Ltd. This transaction represents a strategic financing effort, aimed at furthering the company’s growth initiatives and optimizing its cash flow.
The newly closed debenture comes after an earlier issuance of $450,000 on March 11, 2026, also directed towards Tamar Innovest. The current debenture bears an interest rate of 10% per annum and is set to mature within 12 months from the issuance date or upon the completion of Innocan's proposed public offering in the United States, as disclosed in its registration statement filed with the U.S. Securities and Exchange Commission.
This strategic move is supported by a general security agreement that was established between the involved parties back in March 2025 and is compliant with the legal standards of Alberta province.
Tamar Innovest is noted to hold a significant stake in Innocan, owning approximately 765,020 Common Shares, which translates to 17% of the currently issued shares. The involvement of Tamar Innovest in this offering is classified under related party transactions, given that the firm's management includes Ralph Bossino, a director at Innocan. To comply with regulations, Innocan plans to utilize specific exemptions from valuation and minority approval requirements as prescribed under Multilateral Instrument 61-101. This is justified by the fact that the fair market value associated with the offering does not surpass 25% of the company's assessed market capitalization.
Innocan Pharma has established itself as a pioneer in the fields of pharmaceuticals and wellness. The company specializes in a novel CBD-loaded liposome drug delivery platform that ensures precise dosing and controlled release of synthetic CBD, aimed primarily at non-opioid pain management. Additionally, Innocan is expanding its wellness product line, offering high-performance self-care and beauty items designed to promote healthier lifestyles through its subsidiary, BI Sky Global Ltd, which focuses on advanced online sales solutions.
With its recent fundraising success, Innocan Pharma is well-positioned to enhance its research and development capabilities, ultimately paving the way for innovative product offerings and market expansion. This additional funding is expected to bolster the company's operational framework, paving the way for new strategies and ventures as it continues to evolve within the pharmaceutical landscape.
In conclusion, Innocan Pharma's closure of the additional debenture evidences its strategic financial planning in securing necessary funds to fuel growth and innovation. As the company continues to forge ahead in its mission to improve health and wellness, stakeholders and potential investors will be closely monitoring its developments. The company's commitment to transparency and compliance further solidifies its reputation in the market, ensuring that it navigates potential challenges while remaining focused on its core mission of providing high-quality pharmaceutical solutions.
For more information, please visit Innocan's Official Website.
Details of the Debenture Offering
The newly closed debenture comes after an earlier issuance of $450,000 on March 11, 2026, also directed towards Tamar Innovest. The current debenture bears an interest rate of 10% per annum and is set to mature within 12 months from the issuance date or upon the completion of Innocan's proposed public offering in the United States, as disclosed in its registration statement filed with the U.S. Securities and Exchange Commission.
This strategic move is supported by a general security agreement that was established between the involved parties back in March 2025 and is compliant with the legal standards of Alberta province.
Related Party Transaction Disclosure
Tamar Innovest is noted to hold a significant stake in Innocan, owning approximately 765,020 Common Shares, which translates to 17% of the currently issued shares. The involvement of Tamar Innovest in this offering is classified under related party transactions, given that the firm's management includes Ralph Bossino, a director at Innocan. To comply with regulations, Innocan plans to utilize specific exemptions from valuation and minority approval requirements as prescribed under Multilateral Instrument 61-101. This is justified by the fact that the fair market value associated with the offering does not surpass 25% of the company's assessed market capitalization.
Growth and Future Prospects
Innocan Pharma has established itself as a pioneer in the fields of pharmaceuticals and wellness. The company specializes in a novel CBD-loaded liposome drug delivery platform that ensures precise dosing and controlled release of synthetic CBD, aimed primarily at non-opioid pain management. Additionally, Innocan is expanding its wellness product line, offering high-performance self-care and beauty items designed to promote healthier lifestyles through its subsidiary, BI Sky Global Ltd, which focuses on advanced online sales solutions.
With its recent fundraising success, Innocan Pharma is well-positioned to enhance its research and development capabilities, ultimately paving the way for innovative product offerings and market expansion. This additional funding is expected to bolster the company's operational framework, paving the way for new strategies and ventures as it continues to evolve within the pharmaceutical landscape.
Conclusion
In conclusion, Innocan Pharma's closure of the additional debenture evidences its strategic financial planning in securing necessary funds to fuel growth and innovation. As the company continues to forge ahead in its mission to improve health and wellness, stakeholders and potential investors will be closely monitoring its developments. The company's commitment to transparency and compliance further solidifies its reputation in the market, ensuring that it navigates potential challenges while remaining focused on its core mission of providing high-quality pharmaceutical solutions.
For more information, please visit Innocan's Official Website.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.